AU2006225250A1 - Diagnosis of diseases associated with metastasis - Google Patents
Diagnosis of diseases associated with metastasis Download PDFInfo
- Publication number
- AU2006225250A1 AU2006225250A1 AU2006225250A AU2006225250A AU2006225250A1 AU 2006225250 A1 AU2006225250 A1 AU 2006225250A1 AU 2006225250 A AU2006225250 A AU 2006225250A AU 2006225250 A AU2006225250 A AU 2006225250A AU 2006225250 A1 AU2006225250 A1 AU 2006225250A1
- Authority
- AU
- Australia
- Prior art keywords
- dna
- recited
- genes
- sequences
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010027476 Metastases Diseases 0.000 title claims description 43
- 230000009401 metastasis Effects 0.000 title claims description 42
- 238000003745 diagnosis Methods 0.000 title claims description 21
- 201000010099 disease Diseases 0.000 title claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 52
- 108020004414 DNA Proteins 0.000 claims description 51
- 108091034117 Oligonucleotide Proteins 0.000 claims description 44
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 43
- 230000000295 complement effect Effects 0.000 claims description 37
- 230000011987 methylation Effects 0.000 claims description 34
- 238000007069 methylation reaction Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 21
- 229940104302 cytosine Drugs 0.000 claims description 19
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 230000001973 epigenetic effect Effects 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 108091029430 CpG site Proteins 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 230000030933 DNA methylation on cytosine Effects 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100036364 Cadherin-2 Human genes 0.000 claims description 2
- 102100029758 Cadherin-4 Human genes 0.000 claims description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 2
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 claims description 2
- 101000794580 Homo sapiens Cadherin-4 Proteins 0.000 claims description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 2
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 2
- 101000601855 Homo sapiens Protocadherin-1 Proteins 0.000 claims description 2
- 101000881247 Homo sapiens Spectrin beta chain, erythrocytic Proteins 0.000 claims description 2
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 claims description 2
- 101000612838 Homo sapiens Tetraspanin-7 Proteins 0.000 claims description 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 102100037551 Protocadherin-1 Human genes 0.000 claims description 2
- 102100037613 Spectrin beta chain, erythrocytic Human genes 0.000 claims description 2
- 102100026087 Syndecan-2 Human genes 0.000 claims description 2
- 102100040952 Tetraspanin-7 Human genes 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 230000002962 histologic effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 230000000063 preceeding effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- HJNWFXHIJHRCDT-UHFFFAOYSA-N OS(O)=O.OS(=O)OS(O)=O Chemical compound OS(O)=O.OS(=O)OS(O)=O HJNWFXHIJHRCDT-UHFFFAOYSA-N 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101001015059 Homo sapiens Integrin beta-5 Proteins 0.000 claims 1
- 101000636823 Homo sapiens Neogenin Proteins 0.000 claims 1
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims 1
- 101000823237 Homo sapiens Reticulon-1 Proteins 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100033010 Integrin beta-5 Human genes 0.000 claims 1
- 102100031900 Neogenin Human genes 0.000 claims 1
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 claims 1
- 102100022647 Reticulon-1 Human genes 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229940009188 silver Drugs 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 14
- 230000007067 DNA methylation Effects 0.000 description 10
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000006429 DNA hypomethylation Effects 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- ZCBJDQBSLZREAA-UHFFFAOYSA-N Bisoxatin acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C1(C=2C=CC(OC(C)=O)=CC=2)C(=O)NC2=CC=CC=C2O1 ZCBJDQBSLZREAA-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- -1 Phosphorothioate nucleic acids Chemical class 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100034803 Small nuclear ribonucleoprotein-associated protein N Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000011365 genetic imprinting Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010039827 snRNP Core Proteins Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
P001 Section 29 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: Diagnosis of diseases associated with metastasis The following statement is a full description of this invention, including the best method of performing it known to us: S-1- 0 Diagnosis of Diseases Associated with metastasis l Field of the Invention tt The levels of observation that have been well studied by the methodological developments of recent years in molecular biology, are the genes themselves, the translation of these genes into RNA, and the resulting proteins. The question of which gene is switched on at which point in C71 the course of the development of an individual, and how the activation and inhibition of specific genes in specific cells and tissues are controlled is correlatable to the degree and character of the methylation of the genes or of the genome. In this respect, pathogenic conditions may manifest themselves in a changed methylation pattern of individual genes or of the genome.
The present invention relates to nucleic acids, oligonucleotides, PNA-oligomers and to a method for the diagnosis and/or therapy of diseases which have a connection with the genetic and/or epigenetic parameters of genes associated with metastasis and, in particular, with the methylation status thereof.
Prior Art The key feature of malignant cells is their ability to invade normal healthy tissue and to be disseminated through the body to distant organs. This ability, known as metastasis, is one of the most fatal metastasis of cancer. In breast cancer for example, the extent of metastasis to the lymph nodes is a key prognostic factor of the disease. Approximately 30% of cancers are metastatic at the time of diagnosis, and a further 30-40% of the remaining case harbour occult metastases.
Metastasis is a highly complicated pathway involving multiple proteolytic enzymes, cell adhesion, deformability, cell receptors and motility. Cancer metastasis can be described in the following steps. The initial events involve establishment of the primary tumour. These comprise the initial transforming event and proliferation of the transformed cells followed by evasion of the immune mechanism and establishment of a nutritional supply.
IO
-2o From the primary tumour, metastasis proceeds by local invasion and destruction of extracelt lular matrix and parenchymal cells. It is hypothesised that destruction of the basement membrane proceeds in a two step manner. Firstly, the cancer cell attaches itself to the membrane, this is mediated by the binding of tumour cell surface proteins to glycoproteins, such as In laminin, type IV collagen, and fibronectin. Invasion then proceeds by enzymatic means, both t proteinases (serine, cysteine, aspartic proteinases and metalloproteinases) and tumour secreted C1 hydrolytic enzymes glycosidase, hyaluronidase and heparanase) have been implicated.
C, The next step involves the migration of tumour cells from the primary tumour. The movement of the cells through biological barriers may be driven by a number of factors. These include tumour-derived chemotactic factors, host-derived chemoattractants, and combinations of the two. Studies have shown that tumor cells respond chemotactically to growth factors, collagen, peptides, matrix components and proteolytic fragments of matrix components, adhesion proteins, such as laminin and fibronectin, and tumour-derived attractants. Furthermore, the importance of autocrine growth factors for transformed cell motility has also been demonstrated.
The mobilised cells then attempt to penetrate blood vessel walls. Once the mobilised cells enter the blood stream they are embolized to distant organs. The cells may then be arrested in the lumen of small blood vessels or lymphatics. The cancer cells then proceed to extrude themselves through the walls of the vessels. Establishment of secondary tumours then proceeds by proliferation of the transformed cells followed by evasion of the immune mechanism and establishment of a nutritional supply.
The metastatic pathways involve the recruitment of enzymes used in many different normal pathways. Therefore the key difference between normal cells and malignant cancerous cells can be defined as one of gene regulation. DNA methylation has been implicated as a key regulatory mechanism in tumorigenesis, the role of methylation in tumorigenesis has been reviewed by Singal and Ginder 'DNA Methylation' Blood, Vol. 93 No. 12 (June 15), 1999: pp. 4059-4070. Examples of methylation linked oncogenesis include:
NO
O -3- S Head and neck cancer (Sanchez-Cespedes M et al. ,,Gene promoter hypermethylation in O tumours and serum of head and neck cancer patients,, Cancer Res. 2000 Feb. 15;60 n (4):892-5) -Hodgkin's disease (Garcia JF et al ,,Loss of p16 protein expression associated with methr ylation of the pl6INK4A gene is a frequent finding in Hodgkin's disease,, Lab invest 1999 Q Dec; 79 (12):1453-9)
(N
Gastric cancer (Yanagisawa Y et al. Methylation of the hMLH1 promoter in familial C1 gastric cancer with microsatellite instability,, Int J Cancer 2000 Jan 1; 85 (1):50-3) There is a continuing need to develop new methods of treatment and diagnosis of cancer. The identification of the methylation dependant regulation of cancer genes has opened up the possibility of creating alternative methods of cancer treatment and diagnosis. Treatment with DNA methylation inhibitors has been shown to restore gene expression of the key tumor suppressor genes and oncogenes gene p16, Bender et. al. "Inhibition of DNA methylation by aza-2'-deoxycytidine suppresses the growth of human tumor cell lines." Cancer research 58; 95-101 (1998). This resulted in heritable levels of gene expression leading to suppression of growth in tumor cell lines.
Methylation based therapies could have considerable advantages over current methods of treatment, such as chemotherapy, surgery and radiotherapy. They may even provide a means of treating tumors which are resistant to conventional methods of therapy, as demonstrated by Soengas et al "Inactivation of the apoptosis effector Apaf-1 in malignant melanoma" Nature 409; 207-211(2001). In addition to the development of methylation specific therapies, experiments with Min mice have shown that inhibition of DNA methylation can suppress tumor initiation, Laird et. al. ,,Suppression of intestinal neoplasia by DNA hypomethylation" Cell 81; 197-205 (1995). Furthermore, DNA methylation analysis may provide novel means for cancer diagnosis.
The identification of methylation as a regulatory mechanism, and of the characterisation of the components of the metastatic cascade provides a novel basis for the development of therapies and diagnostics, through the methylation analysis of metastasis related genes.
ID
S-4o 5-methylcytosine is the most frequent covalent base modification in the DNA of eukaryotic
O
t cells. It plays a role, for example, in the regulation of the transcription, in genetic imprinting, and in tumorigenesis. Therefore, the identification of 5-methylcytosine as a component of genetic information is of considerable interest. However, 5-methylcytosine positions cannot t be identified by sequencing since 5-methylcytosine has the same base pairing behavior as V) cytosine. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost CN during PCR amplification.
C1 A relatively new and currently the most frequently used method for analyzing DNA for methylcytosine is based upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behavior. However, 5-methylcytosine remains unmodified under these conditions.
Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridization behavior, can now. be detected as the only remaining cytosine using "normal" molecular biological techniques, for example, by amplification and hybridization or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analyzed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded DNA), and which replaces all precipitation and purification steps with fast dialysis (Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996 Dec 15;24(24):5064-6). Using this method, it is possible to analyze individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analyzed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyze very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.
An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Rein, DePamphilis, M. Zorbas, Nucleic Acids Res. 1998, 26, 2255.
To date, barring few exceptions Zeschnigk M, Lich C, Buiting K, Doerfler W, S Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syn- Sdrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet. 1997 Mar-Apr;5(2):94-8) the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and ei- Sther completely sequenced (Olek A, Walter J. The pre-implantation ontogeny of the H19 0 methylation imprint. Nat Genet. 1997 Nov;17(3):275-6) or individual cytosine positions are C, detected by a primer extension reaction (Gonzalgo ML, Jones PA. Rapid quantitation of Smethylation differences at specific sites using methylation-sensitive single nucleotide primer N extension (Ms-SNuPE). Nucleic Acids Res. 1997 Jun 15;25(12):2529-31, WO 95/00669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997 Jun 15;25(12):2532-4). In addition, detection by hybridization has also been described (Olek et al., WO 99/28498).
Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic DNA. Bioessays. 1994 Jun;16(6):431-6, 431; Zeschnigk M, Schmitz B, Dittrich B, Buiting K, Horsthemke B, Doerfler W. Imprinted segments in the human genome: different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Hum Mol Genet. 1997 Mar;6(3):387-95; Feil R, Charlton J, Bird AP, Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. Nucleic Acids Res. 1994 Feb 25;22(4):695-6; Martin V, Ribieras S, Song-Wang X, Rio MC, Dante R. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region of the pS2 gene and its expression in human breast cancer cell lines. Gene. 1995 May 19;157(1-2):261-4; WO 97 46705, WO 95 15373 and WO 97/45560.
An overview of the Prior Art in oligomer array manufacturing can be gathered from a special edition of Nature Genetics (Nature Genetics Supplement, Volume 21, January 1999), published in January 1999, and from the literature cited therein.
Fluorescently labeled probes are often used for the scanning of immobilized DNA arrays. The simple attachment of Cy3 and Cy5 dyes to the 5'-OH of the specific probe are particularly
\D
-6- C suitable for fluorescence labels. The detection of the fluorescence of the hybridized probes 0 may be carried out, for example via a confocal microscope. Cy3 and Cy5 dyes, besides many t others, are commercially available.
O
Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-TOF) is a very lt efficient development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem.
C 1988 Oct 15;60(20):2299-301). An analyte is embedded in a light-absorbing matrix. The ma- 0 trix is evaporated by a short laser pulse thus transporting the analyte molecule into the vapor
O
C phase in an unfragmented manner. The analyte is ionized by collisions with matrix molecules.
An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, the ions are accelerated at different rates. Smaller ions reach the detector sooner than bigger ones.
MALDI-TOF spectrometry is excellently suited to the analysis of peptides and proteins. The analysis of nucleic acids is somewhat more difficult (Gut I G, Beck S. DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry. Current Innovations and Future Trends. 1995, 1; 147-57). The sensitivity to nucleic acids is approximately 100 times worse than to peptides and decreases disproportionally with increasing fragment size. For nucleic acids having a multiply negatively charged backbone, the ionization process via the matrix is considerably less efficient. In MALDI-TOF spectrometry, the selection of the matrix plays an eminently important role. For the desorption of peptides, several very efficient matrixes have been found which produce a very fine crystallization. There are now several responsive matrixes for DNA, however, the difference in sensitivity has not been reduced. The difference in sensitivity can be reduced by chemically modifying the DNA in such a manner that it becomes more similar to a peptide. Phosphorothioate nucleic acids in which the usual phosphates of the backbone are substituted with thiophosphates can be converted into a chargeneutral DNA using simple alkylation chemistry (Gut IG, Beck S. A procedure for selective DNA alkylation and detection by mass spectrometry. Nucleic Acids Res. 1995 Apr 25;23(8):1367-73). The coupling of a charge tag to this modified DNA results in an increase in sensitivity to the same level as that found for peptides. A further advantage of charge tagging is the increased stability of the analysis against impurities which make the detection of unmodified substrates considerably more difficult.
(O
O-7o Genomic DNA is obtained from DNA of cell, tissue or other test samples using standard t methods. This standard methodology is found in references such as Fritsch and Maniatis eds., Molecular Cloning: A Laboratory Manual, 1989.
f Description tn The object of the present invention is to provide the chemically modified DNA of genes asso- C7, ciated with metastasis, as well as oligonucleotides and/or PNA-oligomers for detecting cyto- Ssine methylations, as well as a method which is particularly suitable for the diagnosis and/or N1 therapy of genetic and epigenetic parameters of genes associated with metastasis. The present invention is based on the discovery that genetic and epigenetic parameters and, in particular, the cytosine methylation pattern of genes associated with metastasis are particularly suitable for the diagnosis and/or therapy of diseases associated with metastasis.
This objective is achieved according to the present invention using a nucleic acid containing a sequence of at least 18 bases in length of the chemically pretreated DNA of genes associated with metastasis according to one of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto. In the table, after the listed gene designations, the respective data bank numbers (accession numbers) are specified which define the appertaining gene sequences as unique. GenBank was used as the underlying data bank, which is located at the National Institute of Health, internet address www.ncbi.nlm.nih.gov.
The chemically modified nucleic acid could heretofore not be connected with the ascertainment of genetic and epigenetic parameters.
The object of the present invention is further achieved by an oligonucleotide or oligomer for detecting the cytosine methylation state in chemically pretreated DNA, containing at least one base sequence having a length of at least 13 nucleotides which hybridizes to a chemically pretreated DNA of genes associated with metastasis according to Seq. ID No.1 through Seq.
ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto. The oli-
NO
-8gomer probes according to the present invention constitute important and effective tools Swhich, for the first time, make it possible to ascertain the genetic and epigenetic parameters of t genes associated with metastasis. The base sequence of the oligomers preferably contains at least one CpG dinucleotide. The probes may also exist in the form of a PNA (peptide nucleic acid) which has particularly preferred pairing properties. Particularly preferred are oligonuf) cleotides according to the present invention in which the cytosine of the CpG dinucleotide is the 5 th 9 th nucleotide from the 5'-end of the 13-mer; in the case of PNA-oligomers, it is preferred for the cytosine of the CpG dinucleotide to be the 4 th 6 th nucleotide from the end of the 9-mer.
The oligomers according to the present invention are normally used in so called "sets" which contain at least one oligomer for each of the CpG dinucleotides of the sequences of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto. Preferred is a set which contains at least one oligomer for each of the CpG dinucleotides from one of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto.
Moreover, the present invention makes available a set of at least two oligonucleotides which can be used as so-called "primer oligonucleotides" for amplifying DNA sequences of one of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto, or segments thereof.
In the case of the sets of oligonucleotides according to the present invention, it is preferred that at least one oligonucleotide is bound to a solid phase.
The present invention moreover relates to a set of at least 10 n (oligonucleotides and/or PNAoligomers) used for detecting the cytosine methylation state in chemically pretreated genomic DNA (Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto). These probes enable diagnosis and/or therapy of genetic and epigenetic
NO
0 -9parameters of genes associated with metastasis. The set of oligomers may also be used for 0 detecting single nucleotide polymorphisms (SNPs) in the chemically pretreated DNA of genes Sassociated with metastasis according to one of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto.
i) According to the present invention, it is preferred that an arrangement of different oligonu- CN cleotides and/or PNA-oligomers (a so-called "array") made available by the present invention 0 is present in a manner that it is likewise bound to a solid phase. This array of different oligo- Ci nucleotide- and/or PNA-oligomer sequences can be characterized in that it is arranged on the solid phase in the form of a rectangular or hexagonal lattice. The solid phase surface is preferably composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold. However, nitrocellulose as well as plastics such as nylon which can exist in the form of pellets or also as resin matrices are possible as well.
Therefore, a further subject matter of the present invention is a method for manufacturing an array fixed to a carrier material for analysis in connection with diseases associated with metastasis in which method at least one oligomer according to the present invention is coupled to a solid phase. Methods for manufacturing such arrays are known, for example, from US Patent 5,744,305 by means of solid-phase chemistry and photolabile protecting groups.
A further subject matter of the present invention relates to a DNA chip for the analysis of diseases associated with metastasis which contains at least one nucleic acid according to the present invention. DNA chips are known, for example, for US Patent 5,837,832.
Moreover, a subject matter of the present invention is a kit which may be composed, for example, of a bisulfite-containing reagent, a set of primer oligonucleotides containing at least two oligonucleotides whose sequences in each case correspond or are complementary to an 18 base long segment of the base sequences specified in the appendix (Seq. ID No.1 through Seq.
ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of the genes according to table 1 and sequences complementary thereto), oligonucleotides and/or PNA-oligomers as well as instructions for carrying out and evaluating the
NO
described method. However, a kit along the lines of the present invention can also contain o only part of the aforementioned components.
The present invention also makes available a method for ascertaining genetic and/or epigenetic parameters of genes associated with the cycle cell by analyzing cytosine methylations t and single nucleotide polymorphisms, including the following steps: C, In the first step of the method, a genomic DNA sample is chemically treated in such a manner \0 Sthat cytosine bases which are unmethylated at the 5'-position are converted to uracil, thymine, CN or another base which is dissimilar to cytosine in terms of hybridization behavior. This will be understood as 'chemical pretreatment' hereinafter.
The genomic DNA to be analyzed is preferably obtained form usual sources of DNA such as cells or cell components, for example, cell lines, biopsies, blood, sputum, stool, urine, cerebral-spinal fluid, tissue embedded in paraffin such as tissue from eyes, intestine, kidney, brain, heart, prostate, lung, breast or liver, histologic object slides, or combinations thereof.
The above described treatment of genomic DNA is preferably carried out with bisulfite (hydrogen sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behavior.
Fragments of the chemically pretreated DNA are amplified, using sets of primer oligonucleotides according to the present invention, and a, preferably heat-stable polymerase. Because of statistical and practical considerations, preferably more than ten different fragments having a length of 100 2000 base pairs are amplified. The amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Usually, the amplification is carried out by means of a polymerase chain reaction (PCR).
In a preferred embodiment of the method, the set of primer oligonucleotides includes at least two olignonucleotides whose sequences are each reverse complementary or identical to an at least 18 base-pair long segment of the base sequences specified in the appendix (Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to
IO
S-11one of the sequences of the genes according to table 1 and sequences complementary thereto).
o The primer oligonucleotides are preferably characterized in that they do not contain any CpG dinucleotides.
O
According to the present invention, it is preferred that at least one primer oligonucleotide is Vn bonded to a solid phase during amplification. The different oligonucleotide and/or PNAn oligomer sequences can be arranged on a plane solid phase in the form of a rectangular or C1 hexagonal lattice, the solid phase surface preferably being composed of silicon, glass, poly- O styrene, aluminium, steel, iron, copper, nickel, silver, or gold, it being possible for other mate- C, rials such as nitrocellulose or plastics to be used as well.
The fragments obtained by means of the amplification can carry a directly or indirectly detectable label. Preferred are labels in the form of fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer, it being preferred that the fragments that are produced have a single positive or negative net charge for better detectability in the mass spectrometer. The detection may be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).
The amplificates obtained in the second step of the method are subsequently hybridized to an array or a set of oligonucleotides and/or PNA probes. In this context, the hybridization takes place in the manner described in the following. The set of probes used during the hybridization is preferably composed of at least 10 oligonucleotides or PNA-oligomers. In the process, the amplificates serve as probes which hybridize to oligonucleotides previously bonded to a solid phase. The non-hybridized fragments are subsequently removed. Said oligonucleotides contain at least one base sequence having a length of 13 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide. The cytosine of the CpG dinucleotide is the 5 t h to 9 th nucleotide from the 5'-end of the 13-mer. One oligonucleotide exists for each CpG dinucleotide. Said PNA-oligomers contain at least one base sequence having a length of 9 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide. The cytosine
\O
0 -12of the CpG dinucleotide is the 4 th to 6 th nucleotide seen from the 5'-end of the 9-mer. One O oligonucleotide exists for each CpG dinucleotide.
In the fourth step of the method, the non-hybridized amplificates are removed.
SIn the final step of the method, the hybridized amplificates are detected. In this context, it is Spreferred that labels attached to the amplificates are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.
C
N According to the present invention, it is preferred that the labels of the amplificates are fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer. The mass spectrometer is preferred for the detection of the amplificates, fragments of the amplificates or of probes which are complementary to the amplificates, it being possible for the detection to be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).
The produced fragments may have a single positive or negative net charge for better detectability in the mass spectrometer. The aforementioned method is preferably used for ascertaining genetic and/or epigenetic parameters of genes associated with metastasis.
The oligomers according to the present invention or arrays thereof as well as a kit according to the present invention are intended to be used for the diagnosis and/or therapy of diseases associated with metastasis by analyzing methylation patterns of genes associated with metastasis. According to the present invention, the method is preferably used for the diagnosis and/or therapy of important genetic and/or epigenetic parameters within genes associated with metastasis.
The method according to the present invention is used, for example, for the diagnosis and/or therapy of solid tumours and cancer.
The nucleic acids according to the present invention of Seq. ID No.1 through Seq. ID No. 198 and sequences complementary thereto and/or of genes according to one of the sequences of
NO
-13the genes according to table I and sequences complementary thereto can be used for the diago nosis and/or therapy of genetic and/or epigenetic parameters of genes associated with metast tasis.
The present invention moreover relates to a method for manufacturing a diagnostic agent t and/or therapeutic agent for the diagnosis and/or therapy of diseases associated with metastat sis by analyzing methylation patterns of genes associated with metastasis, the diagnostic agent N, and/or therapeutic agent being characterized in that at least one nucleic acid according to the
INO
present invention is used for manufacturing it, possibly together with suitable additives and C auxiliary agents.
A further subject matter of the present invention relates to a diagnostic agent and/or therapeutic agent for diseases associated with metastasis by analyzing methylation patterns of genes associated with metastasis, the diagnostic agent and/or therapeutic agent containing at least one nucleic acid according to the present invention, possibly together with suitable additives and auxiliary agents.
The present invention moreover relates to the diagnosis and/or prognosis of events which are disadvantageous to patients or individuals in which important genetic and/or epigenetic parameters within genes associated with metastasis said parameters obtained by means of the present invention may be compared to another set of genetic and/or epigenetic parameters, the differences serving as the basis for a diagnosis and/or prognosis of events which are disadvantageous to patients or individuals.
In the context of the present invention the term "hybridization" is to be understood as a bond of an oligonucleotide to a completely complementary sequence along the lines of the Watson- Crick base pairings in the sample DNA, forming a duplex structure. To be understood by "stringent hybridization conditions" are those conditions in which a hybridization is carried out at 60 0 C in 2.5 x SSC buffer, followed by several washing steps at 37C in a low buffer concentration, and remains stable.
NO
O -14- The term "functional variants" denotes all DNA sequences which are complementary to a O DNA sequence, and which hybridize to the reference sequence under stringent conditions and n have an activity similar to the corresponding polypeptide according to the present invention.
In the context of the present invention, "genetic parameters" are mutations and polymort phisms of genes associated with metastasis and sequences further required for their regulation. To be designated as mutations are, in particular, insertions, deletions, point mutations, inversions and polymorphisms and, particularly preferred, SNPs (single nucleotide polymor- O phisms).
In the context of the present invention, "epigenetic parameters" are, in particular, cytosine methylations and further chemical modifications of DNA bases of genes associated with metastasis and sequences further required for their regulation. Further epigenetic parameters include, for example, the acetylation of histones which, however, cannot be directly analyzed using the described method but which, in turn, correlates with the DNA methylation.
In the following, the present invention will be explained in greater detail on the basis of the sequences and examples without being limited thereto.
Sequence ID Nos. 1 to 198 Sequences having odd sequence numbers Seq. ID No. 1, 3, 5, exhibit in each case sequences of the chemically pretreated genomic DNAs of different genes associated with metastasis. Sequences having even sequence numbers Seq. ID No. 2, 4, 6, exhibit in each case the sequences of the chemically pretreated genomic DNAs of genes associated with metastasis which are complementary to the preceeding sequences the complementary sequence to Seq. ID No.1 is Seq. ID No.2, the complementary sequence to Seq. ID No.3 is Seq. ID No.4, etc.) Sequence ID Nos. 199 to 202 Sequence ID Nos. 199 to 202 show the sequences of oligonucleotides used in Example 1.
The following example relates to a fragment of a gene associated with metastasis, in this case, CD22 in which a specific CG-position is analyzed for its methylation status.
NO
O Example 1:Methylation analysis of the gene CD22 associated with metastasis.
in The following example relates to a fragment of the gene CD22 in which a specific CGposition is to be analyzed for methylation.
t In the first step, a genomic sequence is treated using bisulfite (hydrogen sulfite, disulfite) in l t such a manner that all cytosines which are not methylated at the 5-position of the base are C1 modified in such a manner that a different base is substituted with regard to the base pairing behavior while the cytosines methylated at the 5-position remain unchanged.
If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturating reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of nonmethylated cytosine nucleobases to uracil. The chemically converted DNA (sequence ID No.
159) is then used for the detection of methylated cytosines. In the second method step, the treated DNA sample is diluted with water or an aqueous solution. Preferably, the DNA is subsequently desulfonated (10-30 min, 90-100 at an alkaline pH value. In the third step of the method, the DNA sample is amplified in a polymerase chain reaction, preferably using a heatresistant DNA polymerase. In the present case, cytosines of the gene CD22 are analyzed. To this end, a defined fragment having a length of 470 bp is amplified with the specific primer oligonucleotides TGTGTGTTGTTAAATGAAGA (Sequence ID No. 199) and ACACAAATATTAAAATTATC (Sequence ID No. 200). This amplificate serves as a sample which hybridizes to an oligonucleotide previously bonded to a solid phase, forming a duplex structure, for example TTGTTATACGTTTTGTTT (Sequence ID No. 201), the cytosine to be detected being located at position 210 of the amplificate. The detection of the hybridization product is based on Cy3 and Cy5 fluorescently labelled primer oligonucleotides which have been used for the amplification. A hybridization reaction of the amplified DNA with the oligonucleotide takes place only if a methylated cytosine was present at this location in the bisulfite-treated DNA. Thus, the methylation status of the specific cytosine to be analyzed is inferred from the hybridization product.
In order to verify the methylation status of the position, a sample of the amplificate is further hybridized to another oligonucleotide previously bonded to a solid phase. Said olignonucleo-
NO
O -16tide is identical to the oligonucleotide previously used to analyze the methylation status of the O sample, with the exception of the position in question. At the position to be analysed said oli- Sgonucleotide comprises a thymine base as opposed to a cytosine base i.e TTGTTATATGTTTTGTTT (Sequence ID No. 202). Therefore, the hybridisation reaction only takes place if an unmethylated cytosine was present at the position to be analysed.
tn Example 2: Diagnosis of diseases associated with metastasis 1 In order to relate the methylation patterns to one of the diseases associated with metastasis, it 0 is initially required to analyze the DNA methylation patterns of a group of diseased and of a C group of healthy patients. These analyses are carried out, for example, analogously to Example 1. The results obtained in this manner are stored in a database and the CpG dinucleotides which are methylated differently between the two groups are identified. This can be carried out by determining individual CpG methylation rates as can be done, for example, in a relatively imprecise manner, by sequencing or else, in a very precise manner, by a methylationsensitive "primer extension reaction". It is also possible for the entire methylation status to be analyzed simultaneously, and for the patterns to be compared, for example, by clustering analyses which can be carried out, for example, by a computer.
Subsequently, it is possible to allocate the examined patients to a specific therapy group and to treat these patients selectively with an individualized therapy.
Example 2 can be carried out, for example, for cancer and solid tumours.
Table 1 List of preferred genes associated with metastasis according to the invention Gene Genbank Entry No.
(http://www.ncbi.nlm.nih.gov) L23418 FN1 M10905 SDC2 J04621 ACTG1 NM 001614 CDH2 NM_001792 CDH4 NM_001794 Gene Genbank Entry No.
(http://www.ncbi.nlm.nih.gov) CDW52 NM_00 1803 ITGAX NM_000887 ITGB 1 NM_002211 NM_002213 ITGB7 NM_000889 NEOl NM_002499 PCDH1 NM_002587 ENPPI NM 006208 RTNI NM_021136 SELPLG NM_003006 TM4SF2 NM_004615 ITGAE NM_002208 SPTB NM_000347 ITGBI NM_002211
Claims (32)
1. A nucleic acid comprising a sequence at least 18 bases in length of a segment of the chemi- O cally pretreated DNA of genes associated with metastasis according to one of the sequences taken from the group ofSeq. ID No. 1 to Seq. ID No. 198 and sequences complementary I thereto. C
2. A nucleic acid comprising a sequence at least 18 base pairs in length of the chemically pre- NO treated DNA of genes associated with metastasis according to one of the sequences according C' to one of the genes CD20 (L23418), FN1 (M10905), SDC2 (J04621), ACTGI (NM_001614), CDH2 (NM_001792), CDH4 (NM_001794), CDW52 (NM_001803), ITGAX (NM_000887), NM_002211, ITGB5 (NM_002213), ITGB7 (NM_000889), NEO1 (NM_002499), PCDH1 (NM_002587), ENPP1 (NM_006208), RTN1 (NM_021136), SELPLG (NM_003006), TM4SF2 (NM_004615), ITGAE (NM_002208), SPTB (NM_000347), ITGB1 (NM_002211) and sequences complementary thereto.
3. An oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer comprising in each case at least one base sequence having a length of at least 9 nu- cleotides which hybridizes to or is identical to a chemically pretreated DNA of genes associ- ated with metastasis according to one of the Seq ID Nos 1 to 198 according to claim 1 or to a chemically pretreated DNA of genes according to claim 2 and sequences complementary thereto.
4. The oligomer as recited in Claim 3; wherein the base sequence includes at least one CpG dinucleotide.
The oligomer as recited in Claim 3; characterized in that the cytosine of the CpG dinucleo- tide is located approximately in the middle third of the oligomer.
6. A set of oligomers, comprising at least two oligomers according to any of claims 3 to
7. A set of oligomers as recited in Claim 6, comprising oligomers for detecting the methyla- tion state of all CpG dinucleotides within one of the sequences according to Seq. ID Nos. 1 NO -19- through 198 according to claim 1 or a chemically pretreated DNA of genes according to claim o 2, and sequences complementary thereto. O O
8. A set of at least two oligonucleotides as recited in Claim 3, which can be used as primer oligonucleotides for the amplification of DNA sequences of one of Seq. ID No. 1 through I Seq. ID No. 198 and sequences complementary thereto and/or sequences of a chemically pre- lt treated DNA of genes according to claim 2, and sequences complementary thereto and seg- CI ments thereof. NO Ci
9. A set of oligonucleotides as recited in Claim 8, characterized in that at least one oligonu- cleotide is bound to a solid phase.
Use of a set of oligomer probes comprising at least ten of the oligomers according to any of claims 6 through 9 for detecting the cytosine methylation state and/or single nucleotide polymorphisms (SNPs) in a chemically pretreated genomic DNA according to claim 1 or a chemically pretreated DNA of genes according to claim 2.
11. A method for manufacturing an arrangement of different oligomers (array) fixed to a car- rier material for analyzing diseases associated with the methylation state of the CpG dinu- cleotides of one of the Seq. ID No. 1 through Seq. ID No. 198 and sequences complementary thereto and/or chemically pretreated DNA of genes according to claim 2, wherein at least one oligomer according to any of the claims 3 through 5 is coupled to a solid phase.
12. An arrangement of different oligomers (array) obtainable according to claim 11.
13. An array of different oligonucleotide- and/or PNA-oligomer sequences as recited in Claim 12, characterized in that these are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice.
14. The array as recited in any of the Claims 12 or 13, characterized in that the solid phase surface is composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, sil- ver, or gold. NO O
15. A DNA- and/or PNA-array for analyzing diseases associated with the methylation state of O genes, comprising at least one nucleic acid according to one of the preceeding claims.
16. A method for ascertaining genetic and/or epigenetic parameters for the diagnosis and/or therapy of existing diseases or the predisposition to specific diseases by analyzing cytosine In methylations, V characterized in that the following steps are carried out: N Sa) in a genomic DNA sample, cytosine bases which are unmethylated at the 5-position are (C7 converted, by chemical treatment, to uracil or another base which is dissimilar to cytosine in terms of hybridization behavior; b) fragments of the chemically pretreated genomic DNA are amplified using sets of primer oligonucleotides according to Claim 8 or 9 and a polymerase, the amplificates carrying a de- tectable label; c) Amplificates are hybridized to a set of oligonucleotides and/or PNA probes according to the Claims 6 and 7, or else to an array according to one of the Claims 12 through d) the hybridized amplificates are subsequently detected.
17. The method as recited in Claim 16, characterized in that the chemical treatment is carried out by means of a solution ofa bisulfite, hydrogen sulfite or disulfite.
18. The method as recited in one of the Claims 16 or 17, characterized in that more than ten different fragments having a length of 100 2000 base pairs are amplified.
19. The method as recited in one of the Claims 16 through 18, characterized in that the ampli- fication of several DNA segments is carried out in one reaction vessel.
The method as recited in one of the Claims 16 through 19, characterized in that the poly- merase is a heat-resistant DNA polymerase. \O O -21-
21. The method as recited in Claim 20, characterized in that the amplification is carried out by O means of the polymerase chain reaction (PCR).
22. The method as recited in one of the Claims 16 through 21, characterized in that the labels of the amplificates are fluorescence labels. S23. The method as recited in one of the Claims 16 through 21, characterized in that the labels C of the amplificates are radionuclides.
N1
24. The method as recited in one of the Claims 16 through 21, characterized in that the labels of the amplificates are detachable molecule fragments having a typical mass which are de- tected in a mass spectrometer.
The method as recited in one of the Claims 16 through 21, characterized in that the ampli- ficates or fragments of the amplificates are detected in the mass spectrometer.
26. The method as recited in one of the Claims 24 and/or 25, characterized in that the pro- duced fragments have a single positive or negative net charge for better detectability in the mass spectrometer
27. The method as recited in one of the Claims 24 through 26, characterized in that detection is carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).
28. The method as recited in one of the Claims 16 through 27, characterized in that the geno- mic DNA is obtained from cells or cellular components which contain DNA, sources of DNA comprising, for example, cell lines, biopsies, blood, sputum, stool, urine, cerebral-spinal fluid, tissue embedded in paraffin such as tissue from eyes, intestine, kidney, brain, heart, prostate, lung, breast or liver, histologic object slides, and all possible combinations thereof.
29. A kit comprising a bisulfite disulfite, hydrogen sulfite) reagent as well as oligonucleo- tides and/or PNA-oligomers according to one of the Claims 3 through O- 22-
30. The use of a nucleic acid according to Claims 1 or 2, of an oligonucleotide or PNA- O oligomer according to one of the Claims 3 through 5, of a kit according to Claim 29, of an array according to one of the Claims 12 through 15, of a set of oligonucleotides according to one of claims 6 through 9 for the diagnosis of solid tumours and cancer. 0
31. The use of a nucleic acid according to Claims 1 or 2, of an oligonucleotide or PNA- t oligomer according to one of Claims 3 through 5, of a kit according to Claim 29, of an array "1 according to one of the Claims 12 through 15, of a set of oligonucleotides according to one of 0 claims 6 through 9 for the therapy of solid tumours and cancer.
32. A kit, comprising a bisulfite disulfite, hydrogen sulfite) reagent as well as oligonucleo- tides and/or PNA-oligomers according to one of claims 3 through
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006225250A AU2006225250A1 (en) | 2000-04-06 | 2006-10-05 | Diagnosis of diseases associated with metastasis |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019058.8 | 2000-04-06 | ||
| DE10019173.8 | 2000-04-07 | ||
| DE10032529.7 | 2000-06-30 | ||
| DE10043826.1 | 2000-09-01 | ||
| AU2006225250A AU2006225250A1 (en) | 2000-04-06 | 2006-10-05 | Diagnosis of diseases associated with metastasis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001276331 Division | 2001-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006225250A1 true AU2006225250A1 (en) | 2006-10-26 |
Family
ID=37450646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006225250A Abandoned AU2006225250A1 (en) | 2000-04-06 | 2006-10-05 | Diagnosis of diseases associated with metastasis |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2006225250A1 (en) |
-
2006
- 2006-10-05 AU AU2006225250A patent/AU2006225250A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030148327A1 (en) | Diagnosis of diseases associated with metastasis | |
| US20040048254A1 (en) | Diagnosis of diseases associated with tumor supressor genes and oncogenes | |
| US20080145839A1 (en) | Method and Nucleic Acids For the Differentiation of Astrocytoma, Oligoastrocytoma and Oligodenroglioma Tumor Cells | |
| AU2001276330A1 (en) | Diagnosis of diseases associated with apoptosis | |
| WO2002103042A2 (en) | Method and nucleic acids for the differentiation of prostate tumors | |
| EP1344832A1 (en) | Methods and nucleic acids for the analysis of methylation within the gene melastatin | |
| US20060210976A1 (en) | Methods and nucleic acids for the analysis of methylation patterns within the dd3 gene | |
| AU2006225250A1 (en) | Diagnosis of diseases associated with metastasis | |
| AU2006213968A1 (en) | Diagnosis of diseases associated with DNA replication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |